$91.16
0.11[0.12%]
At close: Apr 25
$91.16
0[0.00%]
After Hours: 4:00PM EDT
Amedisys
(NASDAQ:AMED)Amedisys Stock (NASDAQ:AMED), Analyst Ratings, Price Targets, Predictions
Amedisys Inc has a consensus price target of $123.38, established from looking at the 82 latest analyst ratings. The last 3 analyst ratings were released from Cantor Fitzgerald, Raymond James, and RBC Capital on April 25, 2024, March 26, 2024, and March 25, 2024. With an average price target of $67 between Cantor Fitzgerald, Raymond James, and RBC Capital, there's an implied -26.50% downside for Amedisys Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
Raymond James
RBC Capital
TD Cowen
Credit Suisse
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Amedisys
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/25/2024 | AMED | Buy Now | Amedisys | $91.16 | 10.79% | Cantor Fitzgerald | Sarah James | → $101 | Reiterates | Neutral → Neutral | Get Alert |
| 03/26/2024 | AMED | Buy Now | Amedisys | $91.16 | — | Raymond James | John Ransom | — | Maintains | Market Perform | Get Alert |
| 03/25/2024 | AMED | Buy Now | Amedisys | $91.16 | 9.7% | RBC Capital | Ben Hendrix | $97 → $100 | Maintains | Outperform | Get Alert |
| 09/14/2023 | AMED | Buy Now | Amedisys | $91.16 | 10.79% | Cantor Fitzgerald | Sarah James | $100 → $101 | Maintains | Neutral | Get Alert |
| 07/31/2023 | AMED | Buy Now | Amedisys | $91.16 | 10.79% | TD Cowen | Gary Taylor | $84 → $101 | Maintains | Market Perform | Get Alert |
| 07/27/2023 | AMED | Buy Now | Amedisys | $91.16 | 10.79% | Credit Suisse | Jonathan Yong | → $101 | Reiterates | Neutral → Neutral | Get Alert |
| 07/06/2023 | AMED | Buy Now | Amedisys | $91.16 | 10.79% | Jefferies | Brian Tanquilut | $98 → $101 | Downgrade | Buy → Hold | Get Alert |
| 06/28/2023 | AMED | Buy Now | Amedisys | $91.16 | — | Benchmark | Bill Sutherland | — | Downgrade | Buy → Hold | Get Alert |
| 06/27/2023 | AMED | Buy Now | Amedisys | $91.16 | — | Benchmark | Bill Sutherland | — | Downgrade | Buy → Hold | Get Alert |
| 06/27/2023 | AMED | Buy Now | Amedisys | $91.16 | 10.79% | Truist Securities | David Macdonald | $97 → $101 | Maintains | Hold | Get Alert |
| 06/07/2023 | AMED | Buy Now | Amedisys | $91.16 | 6.41% | Truist Securities | David Macdonald | → $97 | Downgrade | Buy → Hold | Get Alert |
| 06/06/2023 | AMED | Buy Now | Amedisys | $91.16 | 9.7% | Cantor Fitzgerald | Sarah James | $91 → $100 | Maintains | Neutral | Get Alert |
| 06/06/2023 | AMED | Buy Now | Amedisys | $91.16 | 26.15% | Benchmark | Bill Sutherland | → $115 | Reiterates | Buy → Buy | Get Alert |
| 06/06/2023 | AMED | Buy Now | Amedisys | $91.16 | 9.7% | Credit Suisse | Jonathan Yong | $115 → $100 | Downgrade | Outperform → Neutral | Get Alert |
| 05/08/2023 | AMED | Buy Now | Amedisys | $91.16 | -7.85% | TD Cowen | Gary Taylor | $95 → $84 | Maintains | Market Perform | Get Alert |
| 05/05/2023 | AMED | Buy Now | Amedisys | $91.16 | -3.47% | Barclays | Steve Valiquette | $93 → $88 | Maintains | Equal-Weight | Get Alert |
| 05/04/2023 | AMED | Buy Now | Amedisys | $91.16 | 6.41% | Truist Securities | David Macdonald | $115 → $97 | Maintains | Buy | Get Alert |
| 05/04/2023 | AMED | Buy Now | Amedisys | $91.16 | 12.99% | Stephens & Co. | Scott Fidel | → $103 | Reiterates | → Equal-Weight | Get Alert |
| 04/21/2023 | AMED | Buy Now | Amedisys | $91.16 | -4.56% | Cantor Fitzgerald | Sarah James | → $87 | Initiates | → Neutral | Get Alert |
FAQ
What is the target price for Amedisys (AMED)?
The latest price target for Amedisys (NASDAQ: AMED) was reported by Cantor Fitzgerald on April 25, 2024. The analyst firm set a price target for $101.00 expecting AMED to rise to within 12 months (a possible 10.79% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Amedisys (AMED)?
The latest analyst rating for Amedisys (NASDAQ: AMED) was provided by Cantor Fitzgerald, and Amedisys reiterated their neutral rating.
When was the last upgrade for Amedisys (AMED)?
The last upgrade for Amedisys Inc happened on March 1, 2022 when UBS raised their price target to $168. UBS previously had a sell for Amedisys Inc.
When was the last downgrade for Amedisys (AMED)?
The last downgrade for Amedisys Inc happened on July 6, 2023 when Jefferies changed their price target from $98 to $101 for Amedisys Inc.
When is the next analyst rating going to be posted or updated for Amedisys (AMED)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amedisys, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amedisys was filed on April 25, 2024 so you should expect the next rating to be made available sometime around April 25, 2025.
Is the Analyst Rating Amedisys (AMED) correct?
While ratings are subjective and will change, the latest Amedisys (AMED) rating was a reiterated with a price target of $0.00 to $101.00. The current price Amedisys (AMED) is trading at is $91.16, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.